Log in

Relevant bibliographies by topics / Stupp regimen / Journal articles

To see the other types of publications on this topic, follow the link: Stupp regimen.

Journal articles on the topic 'Stupp regimen'

Author: Grafiati

Published: 4 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Stupp regimen.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tanaka, Toshihide, Ryota Tamura, Yohei Yamamoto, et al. "ANGI-01 ALTERATION IN IMMUNE REGULATORY CELLS BEFORE AND AFTER TREATMENT BY STUPP REGIMEN WITH OR WITHOUT BEVACIZUMAB FOR GLIOBLASTOMA." Neuro-Oncology Advances 1, Supplement_2 (2019): ii4—ii5. http://dx.doi.org/10.1093/noajnl/vdz039.019.

Full text

Abstract:

Abstract BACKGROUND In our previous study, bevacizumab (Bev), a humanized anti- vascular endothelial growth factor monoclonal antibody, downregulated the expression of programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) immune checkpoint molecules, suppressed the infiltration of immunosuppressing cells such as regulatory T cells (Tregs) and tumor-associated macrophages (TAMs), and induces cytotoxic T lymphocytes (CTL) infiltration. To explore the possibility that inhibition of immunosuppressive cell infiltration and induction of CTL were attributed to not only Bev alone but a

APA, Harvard, Vancouver, ISO, and other styles

2

Zhou, LF, Yu Yao, Shuyuan Yang, et al. "The Stupp regimen preceded by early post-surgery temozolomide versus the Stupp regimen alone in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM)." Journal of Clinical Oncology 31, no. 15_suppl (2013): 2022. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.2022.

Full text

Abstract:

2022 Background: In treatment of newly diagnosed GBM with the Stupp chemo-radiotherapy regimen, following by adjuvant chemotherapy, patients were treated with temozolomide (TMZ) & combined radiotherapy 4-5 weeks after surgery. In the interval between surgery and chemo-radiotherapy, it is not known whether additional TMZ treatment will improve efficacy or safety. This trial evaluated the safety and efficacy of the Stupp regimen + early post-surgery TMZ chemotherapy in the treatment of patients with newly diagnosed GBM. Methods: The trial was a multi-center, randomized open-label study. 99 n

APA, Harvard, Vancouver, ISO, and other styles

3

Kazda, T., R. Jancalek, R. Belanova, et al. "P14.101 Glioblastoma survival outcomes related to cortical/neural stem cells regions." Neuro-Oncology 21, Supplement_3 (2019): iii91—iii92. http://dx.doi.org/10.1093/neuonc/noz126.336.

Full text

Abstract:

Abstract BACKGROUND Subventricular brain zone (SVZ) and hippocampal regions are supposed to harbor astrocyte-like neural stem cells. While some tumors may arise from transformed SVZ stem cells, other may be initiated by neo-plastic transformation of non-SVZ progenitor cells or mature glial cells. Lim′s et al classification (Neuro-Oncology 2007) of initial glioblastoma location, related to these neural stem cells regions, was predictive for invasive and multifocal tumor phenotype. The aim of this retrospective single-institutional study is to evaluate the relations of this Lim classification on

APA, Harvard, Vancouver, ISO, and other styles

4

Nishikawa, Ryo. "ACT-25 CLINICAL TRIALS BY THE JCOG BRAIN TUMOR STUDY GROUP." Neuro-Oncology Advances 1, Supplement_2 (2019): ii15. http://dx.doi.org/10.1093/noajnl/vdz039.069.

Full text

Abstract:

Abstract Ongoing brain tumor clinical trials by the Japan Clinical Oncology Group (JCOG) are:JCOG1016, phase III randomized study in patients with anaplastic glioma of radiotherapy with temozolomide versus nimustine hydrochloride (ACNU) followed by temozolomide, is to prove superiority of post-operative radiotherapy with ACNU. JCOG1114, phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with primacy CNS lymphoma, is to prove usefulness and get insurance approval of TMZ for primary CNS lymphoma. JCOG1303, rand

APA, Harvard, Vancouver, ISO, and other styles

5

Ilic, Rosanda, Teresa Somma, Dragan Savic, et al. "A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study." World Neurosurg 104, Aug (2017): 581–88. https://doi.org/10.1016/j.wneu.2017.05.018.

Full text

Abstract:

BACKGROUND: Current treatment protocol for glioblastoma multiforme (GBM) is based on maximal safe resection followed by the Stupp protocol. In Serbia, temozolomide was introduced as adjuvant therapy in 2011. The aims of this study were to confirm the safety and efficacy on overall and progression-free survival of the Stupp protocol and evaluate the influence of prognostic factors in one of the largest series of patients with GBM treated over a 2-year period. METHODS: Between January 2010 and December 2012, 110 patients with newly diagnosed GBM underwent surgical removal at the Neurooncology De

APA, Harvard, Vancouver, ISO, and other styles

6

Chen, Yuanyuan, Guihong Liu, Meihua Li, Liang Wang, Pengfei Sun, and Zhongping Chen. "TIPS-11 EFFICACY AND SAFETY OF STUPP REGIMEN WITH OR WITHOUT ANLOTINIB FOR NEWLY DIAGNOSED GLIOBLASTOMA: INTERIM RESULTS OF A MULTICENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL." Neuro-Oncology Advances 5, Supplement_3 (2023): iii36. http://dx.doi.org/10.1093/noajnl/vdad070.142.

Full text

Abstract:

Abstract BACKGROUND Postoperative radiotherapy with concomitant temozolomide (TMZ) followed by ≤ six cycles of adjuvant TMZ chemotherapy (STUPP regimen) is the standard treatment for newly diagnosed glioblastoma (GBM) with limited effectiveness. Anlotinib inhibits both tumor angiogenesis and tumor cell proliferation by targeting multiple kinases, and showing promising results in preclinical GBM models and phase I clinical trials. We designed a phase II trial to verify the efficacy and safety of the STUPP regimen plus anlotinib (NCT 04959500). METHODS This is a multicenter, double-blind, random

APA, Harvard, Vancouver, ISO, and other styles

7

Liu, Yang, Myla Strawderman, Kwanza Warren, et al. "INNV-09. CLINICAL EFFICACY OF TUMOR TREATING FIELDS FOR NEWLY DIAGNOSED GLIOBLASTOMA." Neuro-Oncology 21, Supplement_6 (2019): vi132. http://dx.doi.org/10.1093/neuonc/noz175.552.

Full text

Abstract:

Abstract Recent clinical trials demonstrated that adding tumor treating fields (TTF) to radiotherapy and temozolomide chemotherapy (the Stupp protocol) increased survival for glioblastoma (GBM) patients. However, data is lacking on the magnitude of this survival effect when the regimen is used outside of a clinical trial as part of routine clinical practice. In the present study, we retrospectively identified adult patients with newly diagnosed GBM (n = 240) treated with the Stupp protocol at our institution from January 2005 to July 2017. We grouped patients into two time periods for comparis

APA, Harvard, Vancouver, ISO, and other styles

8

Perlow, Haley, Michael Yang, Brett Klamer, et al. "CTNI-37. ISOEFFECTIVE HYPOFRACTIONATION FOR ELDERLY OR FRAIL PATIENTS WITH A NEWLY DIAGNOSED GLIOBLASTOMA: A POOLED INTERNATIONAL STUDY." Neuro-Oncology 23, Supplement_6 (2021): vi67—vi68. http://dx.doi.org/10.1093/neuonc/noab196.262.

Full text

Abstract:

Abstract PURPOSE The standard of care (SOC) for elderly or frail glioblastoma (GBM) patients is 40 Gy in 15 fraction radiotherapy. However, this regimen has a lower BED compared to the Stupp regimen, 60 Gy in 30 fractions. We hypothesize that isoeffective hypofractionated radiation of 52.5 Gy in 15 fractions (BED equivalent to Stupp) will have superior survival compared to standard of care. METHODS Elderly GBM patients treated with 52.5 Gy in 15 fractions were pooled from 2 phase II studies, 1 phase 1 and a prospective observation study. Overall survival (OS) and progression free survival (PFS

APA, Harvard, Vancouver, ISO, and other styles

9

Chen, Y., G. Liu, P. Sun, et al. "P27.07.A EFFICACY AND SAFETY OF STUPP REGIMEN WITH OR WITHOUT ANLOTINIB FOR NEWLY DIAGNOSED GLIOBLASTOMA: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED PHASE II TRIAL." Neuro-Oncology 26, Supplement_5 (2024): v137—v138. http://dx.doi.org/10.1093/neuonc/noae144.469.

Full text

Abstract:

Abstract BACKGROUND The STUPP regimen, which consists of postoperative radiotherapy with concurrent temozolomide (TMZ) followed by up to six cycles of adjuvant TMZ chemotherapy, is the established standard treatment for newly diagnosed glioblastoma (GBM). However, its effectiveness is limited. Anlotinib, a multi-kinase inhibitor targeting tumor angiogenesis and cell proliferation, has demonstrated promising results in preclinical GBM models and phase I clinical trials. In order to assess the efficacy and safety of combining the STUPP regimen with anlotinib, we conducted a phase II trial aimed

APA, Harvard, Vancouver, ISO, and other styles

10

Miyake, Keisuke, Tomono Fuke, Masaki Tatano, et al. "NI-16 RESPONSE ASSESSMENT OF BEVACIZUMAB THERAPY FOR GLIOBLASTOMA BY USING MULTIPLE PET TRACERS." Neuro-Oncology Advances 4, Supplement_3 (2022): iii18. http://dx.doi.org/10.1093/noajnl/vdac167.067.

Full text

Abstract:

Abstract Objective PET scans are useful for the diagnosis and treatment planning of glioma. Introduced in 2013, bevacizumab (Bev) treatment efficacy can be difficult to determine using MRI imaging. We instead performed PET scans to determine the efficacy of Bev-based glioblastoma treatment. Methods Eighty glioblastoma patients treated with Bev from July 2013 to December 2021 were included. The patients were divided into the following three groups: the first group received Bev added to the Stupp regimen after biopsy or subtotal resection (first-dose group), the second group received Bev added t

APA, Harvard, Vancouver, ISO, and other styles

11

Miyake, Keisuke, Yutaka Yamauchi, Tomono Fuke, et al. "10213-GMC-16 A DECADE REVIEW: BEVACIZUMAB'S IMPACT ON GLIOBLASTOMA TREATMENT." Neuro-Oncology Advances 5, Supplement_5 (2023): v21. http://dx.doi.org/10.1093/noajnl/vdad141.083.

Full text

Abstract:

Abstract OBJECTIVE This study aims to assess the efficacy of Bevacizumab (Bev) therapy, ten years after its initiation in treating glioblastoma patients at our department. METHODS Eighty-four patients treated with Bev from July 2013 to December 2022 were classified into three groups: the initial treatment group given the Stupp regimen with Bev (first-dose group), the group given the Stupp regimen plus Bev followed by tumor resection (neoadjuvant group), and those receiving the Stupp regimen post tumor resection (recurrence group). PET scans were conducted pre- and post- Bev therapy, and variat

APA, Harvard, Vancouver, ISO, and other styles

12

Lapointe, Sarah, Marie Florescu, David Simonyan, and Karine Michaud. "Impact of standard care on elderly glioblastoma patients." Neuro-Oncology Practice 4, no. 1 (2016): 4–14. http://dx.doi.org/10.1093/nop/npw011.

Full text

Abstract:

Abstract Background. Uncertainty persists about the survival advantage of concomitant and adjuvant temozolomide (TMZ) plus radiotherapy (RT) in elderly patients with newly diagnosed glioblastoma (GBM). We compared the clinical outcome of unselected elderly GBM patients treated with 4 adjuvant treatment modalities, including the Stupp protocol. Methods. From 2010 to 2014, retrospective chart review was performed on 171 GBM patients aged ≥55 who received either concurrent chemoradiation therapy (CCRT) with standard 60 Gy/30 (SRT); CCRT with hypofractionated 40 Gy/15 (HRT); HRT alone; or TMZ alon

APA, Harvard, Vancouver, ISO, and other styles

13

Lobbous, Mina, Lawrence S. Lamb, Kate Rochlin, Thriumaine Pillay, Mariska Anouska ter Haak та Louis B. Nabors. "INB-200: Phase 1 study of gene-modified autologous gamma-delta (γδ) t cells in newly diagnosed glioblastoma multiforme (GBM) patients receiving maintenance temozolomide (TMZ)." Journal of Clinical Oncology 43, № 16_suppl (2025): 2007. https://doi.org/10.1200/jco.2025.43.16_suppl.2007.

Full text

Abstract:

2007 Background: Recent cell therapy and CAR-T initiatives for GBM have shown initial responses but durability has been disappointing. We developed a novel approach to treat newly diagnosed GBM using innate γδ T cells following forced upregulation of tumor stress-associated targets. Methods: We leveraged the TMZ-induced activation of the DNA damage response (DDR) pathway to transiently upregulate NKG2D-L targets on GBM. Co-administration of TMZ chemotherapy with γδ T cells engineered for TMZ resistance by insertion of a methylguanine-DNA methyltransferase (MGMT)-expressing lentivector (DeltEx

APA, Harvard, Vancouver, ISO, and other styles

14

Li, Peijing, Yuan yuan Yuan Chen, Shuzhen Lai, et al. "A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM)." Journal of Clinical Oncology 39, no. 15_suppl (2021): 2039. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2039.

Full text

Abstract:

2039 Background: STUPP regimen is now the standard treatment for newly diagnosed GBM, while the effectiveness is limited. This study assessed the efficacy and safety of anlotinib, a multitarget tyrosine kinase inhibitor, combined with the STUPP regimen in treating these patients. Methods: This is a phase II, multicenter, open-label, single-arm trial (NCT04119674). Thirty-three patients (17 males and 16 females) were enrolled from 8 hospitals in China between January 2019 and February 2021. Inclusion criterion included 1) newly diagnosed histologically confirmed glioblastoma (WHO grade IV), 2)

APA, Harvard, Vancouver, ISO, and other styles

15

Jancalek, R., T. Kazda, R. Belanova, et al. "P14.107 Rapid early progression of glioblastoma is not related to cortical/neural stem cells regions." Neuro-Oncology 21, Supplement_3 (2019): iii93. http://dx.doi.org/10.1093/neuonc/noz126.342.

Full text

Abstract:

Abstract BACKGROUND Rapid early progression (REP) of glioblastoma after surgery is quite often observed on pre-radiotherapy MR scan. Clinical and molecular biomarkers indicating increased risk of this REP may be of high clinical need. Subventricular brain zone (SVZ) and hippocampal regions are supposed to harbor astrocyte-like neural stem cells with tumors arising from these transformed SVZ stem cells dreaded to be of higher risk of REP. Lim′s et al classification of initial glioblastoma location related to these neural stem cells regions was predictive for invasive and multifocal tumor phenot

APA, Harvard, Vancouver, ISO, and other styles

16

Bogdahn, U., T. Jauch, C. Beier, et al. "Combined regimen of temozolomide and liposomal pegylated doxorubicin in glioblastoma—Toxicity and efficacy." Journal of Clinical Oncology 24, no. 18_suppl (2006): 11501. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.11501.

Full text

Abstract:

11501 Background: Temozolomide (Temodar, TMZ) recently showed promising efficacy in an EORTC trial on first-line therapy of glioblastoma (Stupp R, 2005). Pegylated liposomal doxorubicin (Caelyx, PEG-DOX) was evaluated in patients with recurrent high-grade glioma and showed an overall response rate of 40% (Hau P, 2002). Therefore, a combination of both agents seems promising. Methods: TMZ was given orally 75 mg/m2 daily during standard radiotherapy (initiation) and 150–200 mg/m2 days 1–5 in 28 days starting 4 weeks after radiotherapy (maintainance). PEG-DOX was given as a short-time infusion in

APA, Harvard, Vancouver, ISO, and other styles

17

Mou, Yonggao, Al-Nahari Fuad, Hao Duan, et al. "SURG-06. FOLLOWING INTRAOPERATIVE TUMOR-FREE PRINCIPLES IS AN EFFECTIVE APPROACH TO IMPROVE SURVIVAL OF PATIENTS WITH GLIOBLASTOMA." Neuro-Oncology 21, Supplement_6 (2019): vi241. http://dx.doi.org/10.1093/neuonc/noz175.1007.

Full text

Abstract:

Abstract The intraoperative tumor-free principles refer to the operation techniques that must be carried out to prevent the exfoliation and planting of tumor cells during the operation, so as to prevent local recurrence and distant metastasis. Following the intraoperative tumor-free principles has been valued in resection of extracranial solid tumors. However, the significance of intraoperative tumor-free principles for brain tumors is still unclear. We retrospectively analyzed 106 patients with primary glioblastoma who underwent resection following the intraoperative tumor-free principles fro

APA, Harvard, Vancouver, ISO, and other styles

18

Kon, Takashi, Yoichi Imaizumi, Yusuke Kobayashi, Yosuke Sato, Katsuyoshi Shimizu, and Tohru Mizutani. "COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery." Neuro-Oncology Advances 2, Supplement_3 (2020): ii22. http://dx.doi.org/10.1093/noajnl/vdaa143.097.

Full text

Abstract:

Abstract Stupp regimen is widely used as the standard treatment after glioblastoma surgery, but in some cases treatment must be discontinued for various reasons. We experienced Bevacizumab in two patients who were unable to continue treatment in the Stupp regimen, and report our experience with literature review. First patient is a man in his 60s. Resection of glioblastoma of the left cerebral hemisphere was performed, and postoperatively right hemiparesis and aphasia remained. Irradiation and administration of Temozolomide were performed, but Temozolomide was unable to continue because of sid

APA, Harvard, Vancouver, ISO, and other styles

19

Pavlov, Vladislav, Philippe Page, Georges Abi-Lahoud, et al. "Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas." British Journal of Neurosurgery 29, no. 4 (2015): 524–31. http://dx.doi.org/10.3109/02688697.2015.1012051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lai, Shuzhen, and Yuanyuan Chen. "CTNI-43. ANLOTINIB COMBINED WITH STUPP REGIMEN IN TREATING PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME: A PHASE II PILOT STUDY." Neuro-Oncology 22, Supplement_2 (2020): ii52. http://dx.doi.org/10.1093/neuonc/noaa215.209.

Full text

Abstract:

Abstract PURPOSE Anlotinib, an orally multi-target tyrosine kinase inhibitor, inhibits tumor angiogenic and proliferative signal pathways. We performed a phase II trial of anlotinib in combination with the STUPP regimen in patients with newly diagnosed glioblastoma multiforme（GBM）to determine whether the combination therapy would safely improve outcomes in this group of patients. An initial pilot study assessed interim safety and tolerability. METHODS AND MATERIALS Ten newly diagnosed GBM patients were included in this study. All patients received standard radiation of 60 Gy in 30 fractions st

APA, Harvard, Vancouver, ISO, and other styles

21

Salmaggi, Andrea, Ida Milanesi, Antonio Silvani, et al. "Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results." Journal of Neurosurgery 118, no. 4 (2013): 821–29. http://dx.doi.org/10.3171/2012.12.jns111893.

Full text

Abstract:

Object Locoregional chemotherapy with carmustine wafers, positioned at surgery and followed by radiation therapy, has been shown to prolong survival in patients with newly diagnosed glioblastoma, as has concomitant radiochemotherapy with temozolomide. A combination of carmustine wafers with the Stupp treatment regimen has only been investigated in retrospective studies. Methods In a single-institution prospective study, the authors assessed 12-month progression-free survival (PFS), toxicity, and overall survival in patients with glioblastoma treated with surgery, carmustine wafers, radiotherap

APA, Harvard, Vancouver, ISO, and other styles

22

Liu, Jing, Liangfang Shen, Guyu Tang, et al. "Multiple extracranial metastases from glioblastoma multiforme: a case report and literature review." Journal of International Medical Research 48, no. 6 (2020): 030006052093045. http://dx.doi.org/10.1177/0300060520930459.

Full text

Abstract:

Extracranial metastasis from glioblastoma multiforme (GBM) is rare, especially multi-site metastases without intracranial recurrence. However, the metastatic mechanism of GBM remains unknown and there is currently no consensus regarding the best therapeutic regimen. We report the case of a 46-year-old man with primary GBM who developed scalp metastases and subsequent multiple pulmonary metastases. He was treated with the Stupp regimen after surgery for the intracranial tumor. However, a series of soft masses in the scalp were subsequently identified, and new nodules were found in his left eyeb

APA, Harvard, Vancouver, ISO, and other styles

23

Rousseau, Julien, Sara-Maude Desforges, Gilbert Jabbour, et al. "BIOS-02. CLINICAL OUTCOMES OF OVER 600 PATIENTS WITH GLIOBLASTOMA TREATED AT A CANADIAN TERTIARY CENTER IN THE PAST 15 YEARS: A COMPARATIVE ANALYSIS WITH THE PIVOTAL STUPP TRIAL." Neuro-Oncology 24, Supplement_7 (2022): vii20—vii21. http://dx.doi.org/10.1093/neuonc/noac209.078.

Full text

Abstract:

Abstract Glioblastoma is the most common malignant primary central nervous system tumor in adults and is associated with a poor prognosis. The benefit of adding concomitant followed by adjuvant temozolomide to radiotherapy after maximal safe resection was demonstrated by Stupp and colleagues in 2005 and has since remained the standard of care. This regimen conferred a statistically significant benefit with a 2-year survival rate of 26.5% compared to 10.4% in patients treated with radiotherapy alone. Our primary goal was to retrospectively assess the clinical outcomes of patients with glioblast

APA, Harvard, Vancouver, ISO, and other styles

24

Rousseau, Julien, Moujahed Labidi, Jean-Paul Bahary, Karl Bélanger, France Berthelet, and Sarah Lapointe. "PATH-10. A CASE OF ADULT THALAMIC DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED WITH AN IMPRESSIVE RESPONSE TO RADIOTHERAPY AND CONCOMITANT PLUS ADJUVANT TEMOZOLOMIDE." Neuro-Oncology 24, Supplement_7 (2022): vii151—vii152. http://dx.doi.org/10.1093/neuonc/noac209.583.

Full text

Abstract:

Abstract Diffuse midline glioma (DMG), H3 K27-altered is a newly defined diagnosis in the 2021 WHO Classification of Tumors of the Central Nervous System. H3 K27 alterations are associated with a uniformly poor prognosis in children with DMG, but they have been linked to improved survival in adults. Clinical experience in adults with DMG, H3 K27M-altered remains limited. Consequently, there exists a knowledge gap regarding the optimal management and responsiveness to chemoradiation therapy, which translates into the current absence of standard treatment. Here we present the case of an 18-year-

APA, Harvard, Vancouver, ISO, and other styles

25

Miyake, Keisuke, Kanda Takahiro, Kenta Suzuki, et al. "NIMG-58. PET IMAGING AS A RELIABLE INDICATOR FOR EVALUATING BEVACIZUMAB TREATMENT RESPONSE IN GBM." Neuro-Oncology 25, Supplement_5 (2023): v199. http://dx.doi.org/10.1093/neuonc/noad179.0754.

Full text

Abstract:

Abstract OBJECTIVE PET scans are crucial for glioma diagnosis and treatment planning, but assessing the efficacy of Bevacizumab (Bev) treatment using MRI alone is challenging. Our study aimed to evaluate the effectiveness of Bev-based glioblastoma treatment using PET scans. METHODS We included ninety glioblastoma patients treated with Bev between July 2013 and May 2023. Patients were divided into three groups: the first group received Bev in addition to the Stupp regimen after biopsy or subtotal resection (first-dose group), the second group received Bev after biopsy followed by tumor resectio

APA, Harvard, Vancouver, ISO, and other styles

26

Aubry, M., A. Etcheverry, A. Idbaih, et al. "802 ORAL Epigenetic Markers Identify MGMT-methylated Glioblastoma Poorly Responding to Combined Radiotherapy-temozolomide (Stupp Regimen)." European Journal of Cancer 47 (September 2011): S95. http://dx.doi.org/10.1016/s0959-8049(11)70639-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Lakomy, Radek, Tomas Kazda, Iveta Selingerova, et al. "Pre-Radiotherapy Progression after Surgery of Newly Diagnosed Glioblastoma: Corroboration of New Prognostic Variable." Diagnostics 10, no. 9 (2020): 676. http://dx.doi.org/10.3390/diagnostics10090676.

Full text

Abstract:

Background: The aim of this retrospective study is to assess the incidence, localization, and potential predictors of rapid early progression (REP) prior to initiation of radiotherapy in newly diagnosed glioblastoma patients and to compare survival outcomes in cohorts with or without REP in relation to the treatment. Methods: We assessed a consecutive cohort of 155 patients with histologically confirmed irradiated glioblastoma from 1/2014 to 12/2017. A total of 90 patients with preoperative, postoperative, and planning MRI were analyzed. Results: Median age 59 years, 59% men, and 39 patients (

APA, Harvard, Vancouver, ISO, and other styles

28

Lombardi, Giuseppe, Gian Luca De Salvo, Marica Eoli, et al. "REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS)." Journal of Clinical Oncology 35, no. 15_suppl (2017): TPS2085. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.tps2085.

Full text

Abstract:

TPS2085 Background: GBM is the most common and malignant form of primary brain tumor with a high recurrence rate after surgery, radiation therapy and temozolomide. Currently, there is no established regimen for the treatment of recurrent GBM. GBMs are highly vascularized tumors with high expression of pro-angiogenic factors and activation of multiple signaling pathways in the tumor microenvironment, including the receptor tyrosine kinases, VEGFR, FGFR, and PDGFR, which control the tumor vasculature. REG, an oral multikinase inhibitor, inhibits these angiogenic kinases and the mutant oncogenic

APA, Harvard, Vancouver, ISO, and other styles

29

Zhu, Ping, and Clark Chen. "EPID-24. TIMING OF STANDARD-OF-CARE CHEMO-RADIATION THERAPY FOLLOWING SURGICAL RESECTION OR STEREOTACTIC BIOPSY." Neuro-Oncology 24, Supplement_7 (2022): vii114—vii115. http://dx.doi.org/10.1093/neuonc/noac209.434.

Full text

Abstract:

Abstract OBJECT The literature examining the optimal timing for initiating post-surgical therapy after glioblastoma surgery is brimming with inconsistencies, with reports of both deleterious effects and benefits in the delay of post-surgical therapy at various time intervals. Moreover, there is currently limited data pertinent to the post-Stupp regimen era. Here, we use the National Cancer Database (NCDB) to explore this matter, with a focus on patients who underwent the standard-of-care (SOC) Stupp regimen. METHODS The study cohort included newly glioblastoma patients from the NCDB, with excl

APA, Harvard, Vancouver, ISO, and other styles

30

Kempter, J., J. Gempt, B. Wiestler, et al. "P11.22.A Prognostic and predictive relevance of immunohistochemically determined p53 mutation in glioblastoma." Neuro-Oncology 24, Supplement_2 (2022): ii61. http://dx.doi.org/10.1093/neuonc/noac174.211.

Full text

Abstract:

Abstract Background It can be expected that molecular biomarkers will increasingly affect clinical decisions and lead to the development of more personalized therapies in glioblastoma (GBM) in the future. In several other tumor entities TP53 gene mutation or p53 immunoreactivity (IR) serve as a prognostic marker, significantly affecting overall survival (OS) and progression-free survival (PFS). Such an association has not yet sufficiently been demonstrated in GBM. However, there are known prognostic markers in GBM, notably MGMT promotor methylation (mMGMT) which also serves as an important pre

APA, Harvard, Vancouver, ISO, and other styles

31

Gallego, O., A. Estival, M. Martinez-Garcia, et al. "Characteristics of gliobastomas (GBM) not resected (only biopsied) homogeneosuly treated with Stupp regimen. Results from the GLIOCAT study." Annals of Oncology 27 (October 2016): vi111. http://dx.doi.org/10.1093/annonc/mdw367.26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Kazda, T., R. Lakomy, I. Selingerova, et al. "P14.59 Rapid early progression of glioblastoma is not related to cortical/neural stem cells regions." Neuro-Oncology 23, Supplement_2 (2021): ii49. http://dx.doi.org/10.1093/neuonc/noab180.170.

Full text

Abstract:

Abstract BACKGROUND Rapid early progression (REP) of glioblastoma after surgery observed on pre-radiotherapy MRI scan is common. Subventricular zone (SVZ) and hippocampal regions are supposed to harbor astrocyte-like neural stem cells (NSC) with tumors arising from these transformed stem cells threatening of higher risk of REP. REP is defined as a new enhancing tumor or &gt;25% increase in enhancement before radiotherapy. Lim′s classification of initial glioblastoma location related to these NSC regions predicts invasive and multifocal tumor phenotype. Glioblastomas are classified preopera

APA, Harvard, Vancouver, ISO, and other styles

33

Chen, Y., G. Liu, P. Sun, et al. "Efficacy and Safety of STUPP Regimen ± Anlotinib for Newly Diagnosed Glioblastoma: A Multicenter, Double-Blind, Randomized Phase II Trial." International Journal of Radiation Oncology*Biology*Physics 120, no. 2 (2024): e223-e224. http://dx.doi.org/10.1016/j.ijrobp.2024.07.503.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Pedersini, R., E. Vattemi, M. Lusso, et al. "Adjuvant chemotherapy with temozolomide and radiation therapy in patients with high grade gliomas." Journal of Clinical Oncology 25, no. 18_suppl (2007): 12534. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.12534.

Full text

Abstract:

12534 Background: Temozolomide, a novel alkylating agent, has shown activity in the treatment of patients with high-grade gliomas. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant chemo- radiotherapy according to Stupp regimen. Methods: We reviewed our experience with a combination of radiotherapy (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week

APA, Harvard, Vancouver, ISO, and other styles

35

Koehler, Abigail, Aniruddha Karve, Pankaj Desai, et al. "Reuse of Molecules for Glioblastoma Therapy." Pharmaceuticals 14, no. 2 (2021): 99. http://dx.doi.org/10.3390/ph14020099.

Full text

Abstract:

Glioblastoma multiforme (GBM) is a highly malignant primary brain tumor. The current standard of care for GBM is the Stupp protocol which includes surgical resection, followed by radiotherapy concomitant with the DNA alkylator temozolomide; however, survival under this treatment regimen is an abysmal 12–18 months. New and emerging treatments include the application of a physical device, non-invasive ‘tumor treating fields’ (TTFs), including its concomitant use with standard of care; and varied vaccines and immunotherapeutics being trialed. Some of these approaches have extended life by a few m

APA, Harvard, Vancouver, ISO, and other styles

36

Lobbous, Mina, Trishna Goswami, Larry Lamb та ін. "CTIM-09. INB-200: FULLY ENROLLED PHASE 1 STUDY OF GENE-MODIFIED AUTOLOGOUS GAMMA-DELTA (ΓΔ) T CELLS IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS RECEIVING MAINTENANCE TEMOZOLOMIDE (TMZ)". Neuro-Oncology 26, Supplement_8 (2024): viii86. http://dx.doi.org/10.1093/neuonc/noae165.0342.

Full text

Abstract:

Abstract IN8bio’s DeltEx drug resistant immunotherapy (DRI), comprising TMZ-resistant γδ T cells engineered to express methylguanine-DNA methyltransferase (MGMT), enables γδ T cells to target upregulated NKG2D ligands on tumor cells in real time during alkylating chemotherapy exposure. Updated results from the fully enrolled Phase 1 trial evaluating DRI in adult newly diagnosed GBM subjects with IDH wild type and mutant tumors, adequate organ function and KPS ≥ 70%. Cohorts (C) 1, 2 and 3 received 1, 3 or 6 doses (1 x 107 DRI cells/dose) into the resection cavity with 150 mg/m2 of IV TMZ on Da

APA, Harvard, Vancouver, ISO, and other styles

37

Lieberman, F. S., C. Tsien, B. Berkey, et al. "Phase II trial of concomitant low dose temozolomide with external beam radiation (EBRT) followed by 12 months of temozolomide and irinotecan for newly diagnosed glioblastoma (GBM): Preliminary results of RTOG 04–20." Journal of Clinical Oncology 24, no. 18_suppl (2006): 1510. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.1510.

Full text

Abstract:

1510 Background: Irinotecan and temozolomide compare favorably to regimens tested in recurrent GBM. RTOG 04–20 intensifies the Stupp R, et al. (N Engl J Med. 2005 Mar 10;352(10):987–96) adjuvant regimen, using irinotecan and temozolomide in place of temozolomide alone. Methods: Adult patients with newly diagnosed histologically confirmed, supratentorial GBM were eligible. Subjects began temozolomide 75mg/m2 daily the night before initiation of EBRT, and continued until the final day of RT. Pneumocystis prophylaxis was begun prior to RT and for 2 weeks following RT. Within 6 wks after EBRT, sub

APA, Harvard, Vancouver, ISO, and other styles

38

Vilarino, Noelia, Neus Martinez-Bosch, Carmen Balana, et al. "Galectin-1 (Gal-1) expression as a prognostic factor in patients with newly diagnosed glioblastoma (GB) treated with Stupp regimen (GLIOCAT study)." Journal of Clinical Oncology 35, no. 15_suppl (2017): e13526-e13526. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e13526.

Full text

Abstract:

e13526 Background: Gal-1 is a β-galactoside binding protein that plays an important role in cancer, promoting cell invasion, proliferation, migration, angiogenesis and evasion of the immune response. Gal-1 is involved in glioma progression and is related to tumor grade and poor clinical outcome. Gal-1 has been implicated in resistance to chemotherapy and as a potential mediator of resistance to anti-VEGF therapy. The aim of our study was to evaluate the prognostic significance of Gal-1 in a homogenous cohort of GB patients and to analyze its potential predictive value of response to bevacizuma

APA, Harvard, Vancouver, ISO, and other styles

39

Pustchi, Sadaf E., Naze G. Avci, Yasemin M. Akay, and Metin Akay. "Astrocytes Decreased the Sensitivity of Glioblastoma Cells to Temozolomide and Bay 11-7082." International Journal of Molecular Sciences 21, no. 19 (2020): 7154. http://dx.doi.org/10.3390/ijms21197154.

Full text

Abstract:

Glioblastoma multiforme (GBM) is the most common malignant type of astrocytic tumors. GBM patients have a poor prognosis with a median survival of approximately 15 months despite the “Stupp” Regimen and high tumor recurrence due to the tumor resistance to chemotherapy. In this study, we co-cultured GBM cells with human astrocytes in three-dimensional (3D) poly(ethylene glycol) dimethyl acrylate (PEGDA) microwells to mimic the tumor microenvironment. We treated 3D co- and mono-cultured cells with Temozolomide (TMZ) and the nuclear factor-κB (NF-κB) inhibitor Bay 11-7082 and investigated the com

APA, Harvard, Vancouver, ISO, and other styles

40

Pineda, Estela, Maria Martinez, Francesc Alameda, et al. "Long-term survivors in glioblastoma patients homogeneously treated with the Stupp regimen, clinical characteristics and MGMT status: Initial results from the GLIOCAT study." Journal of Clinical Oncology 34, no. 15_suppl (2016): e13513-e13513. http://dx.doi.org/10.1200/jco.2016.34.15_suppl.e13513.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Epaillard, Nicolas, Nassim Hammoudi, Matthieu Faron, et al. "CTIM-01. GLIOBLASTOMA RE-IRRADIATION: IMPACT OF CONCOMITANT CHEMOTHERAPY." Neuro-Oncology 22, Supplement_2 (2020): ii32. http://dx.doi.org/10.1093/neuonc/noaa215.135.

Full text

Abstract:

Abstract PURPOSE Although the standard of initial treatment is well defined for glioblastoma, no recommendation exists in the relapse setting. This work focuses on the optimal strategy for recurrent glioblastoma. METHODS Retrospective monocentric analysis of all recurrent glioblastoma adult patients treated since 2000 in one center by re-irradiation, alone or combined with chemotherapy and/or surgery at first or second relapse. RESULTS Patient (n=61) median age was 55 (27 to 76), 44% were women. At diagnosis, 77% underwent surgical resection and 23% were biopsied. Most (95%) received a Stupp r

APA, Harvard, Vancouver, ISO, and other styles

42

Lamb, Lawrence S., Lei Ding, Ryan C. Miller та ін. "Abstract 1173: Maintenance-phase Temozolomide as a lymphodepletion platform for intracranialadoptiveγδ T cell-basedtherapy in primary high-grade gliomas". Cancer Research 82, № 12_Supplement (2022): 1173. http://dx.doi.org/10.1158/1538-7445.am2022-1173.

Full text

Abstract:

Abstract Introduction: Lymphodepletion is a key factor for responses in both autologous and allogeneic cell therapies. We are currently evaluating in a Phase I trial, the combination of Temozolomide (TMZ) chemotherapy with methylguanine-DNA methyltransferase (MGMT) modified γδ T cells (Drug Resistant Immunotherapy, or DRI) during maintenance TMZ in patients receiving the Stupp protocol. In this report, we examine both DRI graft and circulating lymphocyte phenotype and function during the treatment phase. Methods: Patients meeting enrollment criteria undergo tumor resection, placement of a Rick

APA, Harvard, Vancouver, ISO, and other styles

43

Sasame, Jo, Kensuke Tateishi, Naoki Ikegaya, et al. "HGG-51. PAIRED EPITHELIOID GLIOBLASTOMA PATIENT DERIVED XENOGRAFT MODELS WITH/WITHOUT MOLECULAR TARGET THERAPY." Neuro-Oncology 22, Supplement_3 (2020): iii353. http://dx.doi.org/10.1093/neuonc/noaa222.331.

Full text

Abstract:

Abstract Epithelioid glioblastoma (E-GBM) predominantly arises at younger age and promotes dismal prognosis. Because of its rare etiology, pathological and genetical characterization of E-GBM remains elusive. Herein, we report 2 patient-derived E-GBM xenograft (PDX) models from young adult patients (YMG62 and YMG89) with BRAFV600E and TERT promoter mutation. The YMG62 patient received dabrafenib with trametinib, while YMG89 patient received dabrafenib monotherapy after recurrence with Stupp regimen. These molecular target therapies were initially responded, but gradually became resistant (YMG6

APA, Harvard, Vancouver, ISO, and other styles

44

Li, Zhiyong, Xi'an Zhang, Tianshi Que, et al. "Abstract 3252: TTFields combined with temozolomide and immunotherapy show long-term PFS on a GBM patients with multiple negative prognostic factors." Cancer Research 83, no. 7_Supplement (2023): 3252. http://dx.doi.org/10.1158/1538-7445.am2023-3252.

Full text

Abstract:

Abstract Glioblastoma (GBM) is a common CNS tumor with poor prognosis. The median progression-free survival (mPFS) of standard Stupp regimen was about 6.9 months. The 2-THE-TOP study suggested that a triple regimen of temozolomide (TMZ) combined with pembrolizumab and Tumor treating fields (TTFields) could further prolong the mPFS of newly diagnosed GBM to 12.1 months. Here we report a case showing long PFS from this triple regimen. In October 2019, a 60-year-old female patient was admitted to the hospital due to intermittent dizziness and headache with rapid progression of left limb weakness

APA, Harvard, Vancouver, ISO, and other styles

45

Quarrell, Thomas Matthew, Zack Millar, Gary Doherty, Rajesh Jena, and Fiona Harris. "Treatment of Glioblastoma Multiforme at Progression or Recurrence: A Service Evaluation." Neuro-Oncology 24, Supplement_4 (2022): iv21. http://dx.doi.org/10.1093/neuonc/noac200.097.

Full text

Abstract:

Abstract AIMS After initial treatment, glioblastoma multiforme (GBM) invariably reoccurs or progresses. When this happens, there is no established standard of care and treatment choice is made on a case-by-case basis. In our service, there is a multidisciplinary approach to progression, with oncologists and surgeons cooperating closely. This means that our cohort is ideal for studying treatment at progression. METHOD We performed a retrospective cohort service evaluation on patients diagnosed with isocitrate dehydrogenase wildtype GBM over a 4-year, 5-month period. We focused on patients who h

APA, Harvard, Vancouver, ISO, and other styles

46

Pineda, E., M. Martinez-Garcia, A. Estival, et al. "Long-term survivors (LTS) in glioblastoma (GBM) patients (pts) homogeneously treated with the Stupp regimen, clinical and molecular characteristics (MGMT and IDH1 status). Initial results from the GLIOCAT study." Annals of Oncology 27 (October 2016): vi110. http://dx.doi.org/10.1093/annonc/mdw367.25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Lombardi, G., S. Scoccianti, M. G. Fabrini, et al. "2900 Predictors of survival in glioblastoma patients treated with fotemustine at first relapse after Stupp regimen: Analysis of GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology)." European Journal of Cancer 51 (September 2015): S584. http://dx.doi.org/10.1016/s0959-8049(15)30054-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Ruda, Roberta, Giuseppe Lombardi, Silvia Scoccianti, et al. "GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen." Journal of Clinical Oncology 33, no. 15_suppl (2015): 2054. http://dx.doi.org/10.1200/jco.2015.33.15_suppl.2054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Lai, Shuzhen, Peijing Li, Xiaohui Liu, et al. "Mutational profiling of newly diagnosed glioblastoma to identify predictive biomarkers of efficacy and safety of anlotinib combination therapy." Journal of Clinical Oncology 41, no. 16_suppl (2023): e14037-e14037. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e14037.

Full text

Abstract:

e14037 Background: Glioblastoma (GBM) is highly vascular tumor with the specific pathologic feature of microvascular proliferation. Our previous phase Ⅱ clinical trial (NCT04119674) has firstly demonstrated the antiangiogenic multikinase inhibitor anlotinib combined with STUPP regimen can lengthen progression-free survival (PFS) in patients with newly diagnosed GBM. However, no biomarker for angiogenic therapy has been proved yet. Therefore, the second analysis was performed to identify the predictive biomarkers. Methods: A total of 21 patients with newly diagnosed GBM were enrolled in the ret

APA, Harvard, Vancouver, ISO, and other styles

50

Chen, Zhihua, Denis O’Meally, David Frankhouser, et al. "PATH-06. DNA METHYLATION PATTERNS AND IMMUNE MICROENVIRONMENT IN CYSTICGBM." Neuro-Oncology 23, Supplement_6 (2021): vi115—vi116. http://dx.doi.org/10.1093/neuonc/noab196.458.

Full text

Abstract:

Abstract As a rare subtype of glioblastomas (GBM), genetic features in cystic GBM (cGBM) are still largely unknown. We have previously identified a series of active T cell subsets and positive cytokines/chemocytokines in the cystic fluid of cGBMs, including IFN-gamma, IL-2, IL-6, IL-8, TNF-alpha, and MIP-1alpha/beta. This study aimed to evaluate the prognosis of cGBM through DNA methylation patterns and immune microenvironment transcriptional signatures. IvyGAP, EGA and fresh samples from a prospective Chinese cohort were collected to investigate genomic signatures, immune microenvironment and

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!